InMed’s VP, Sales & Marketing, Jerry P. Griffin, talks about how the market for bioidentical rare cannabinoids has changed over the past year.
Jerry contributes these market changes to research and consumer education on rare cannabinoids and the interest of Health and Wellness companies to make innovative new products.
In this interview with Benzinga, Jerry explains how the market has become more receptive to bioidentical rare cannabinoids and how bioidentical rare cannabinoids can fill a need for consumer packaged goods (CPG) companies requiring large scale, batch-to-batch consistency to produce their health and wellness products.
BayMedica’s flagship product is CBC with recent sales increasing 46% from the previous quarter.
Read the article and watch the video on Benzinga.
